EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB
The article contains results of the study of efficacy and safety of adalimumab treatment given to 110 patients with juvenile idiopathic arthritis (JIA) and arthritis with eye-lesions, refractory to classical immunosuppressive treatment. Follow up period was from 3 monthsto 1 year long. The dosage re...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2012-01-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/519 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849692063581339648 |
|---|---|
| author | E. I. Alexeeva E. V. Mitenko S. I. Valieva T. M. Bzarova R. V. Denisova K. B. Isaeva T. V. Sleptsova A. M. Tchomakhidze |
| author_facet | E. I. Alexeeva E. V. Mitenko S. I. Valieva T. M. Bzarova R. V. Denisova K. B. Isaeva T. V. Sleptsova A. M. Tchomakhidze |
| author_sort | E. I. Alexeeva |
| collection | DOAJ |
| description | The article contains results of the study of efficacy and safety of adalimumab treatment given to 110 patients with juvenile idiopathic arthritis (JIA) and arthritis with eye-lesions, refractory to classical immunosuppressive treatment. Follow up period was from 3 monthsto 1 year long. The dosage regimen was as follows — 1 subcutaneous injection of Adalimumab 40 mg once in 2 weeks. Against the background of treatment with anti-TNF agents clinical remission, decrease and normalization of lab parameters of the disease activity, lower degree of disability, quality of life increase in 100 patients (90%), decrease in uveitis activity (N = 9, 18.75%), and remission of uveitis (N=39, 81.25%) were achieved. During the follow up period there were no adverse events that lead to drug withdrawal. Thereby, Adalimumab treatment is pathogenetically justified, effective and safe for patients with JIA and uveitis. |
| format | Article |
| id | doaj-art-484aea61b8b043cb8e2c0b3b731dbe69 |
| institution | DOAJ |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-484aea61b8b043cb8e2c0b3b731dbe692025-08-20T03:20:50Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352012-01-0111111111810.15690/vsp.v11i1.141519EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMABE. I. Alexeeva0E. V. Mitenko1S. I. Valieva2T. M. Bzarova3R. V. Denisova4K. B. Isaeva5T. V. Sleptsova6A. M. Tchomakhidze7Scientific Centre of Children’s Health RAMS, Moscow Sechenov First Moscow Medical UniversityScientific Centre of Children’s Health RAMS, MoscowScientific Centre of Children’s Health RAMS, MoscowScientific Centre of Children’s Health RAMS, MoscowScientific Centre of Children’s Health RAMS, MoscowScientific Centre of Children’s Health RAMS, MoscowScientific Centre of Children’s Health RAMS, MoscowScientific Centre of Children’s Health RAMS, MoscowThe article contains results of the study of efficacy and safety of adalimumab treatment given to 110 patients with juvenile idiopathic arthritis (JIA) and arthritis with eye-lesions, refractory to classical immunosuppressive treatment. Follow up period was from 3 monthsto 1 year long. The dosage regimen was as follows — 1 subcutaneous injection of Adalimumab 40 mg once in 2 weeks. Against the background of treatment with anti-TNF agents clinical remission, decrease and normalization of lab parameters of the disease activity, lower degree of disability, quality of life increase in 100 patients (90%), decrease in uveitis activity (N = 9, 18.75%), and remission of uveitis (N=39, 81.25%) were achieved. During the follow up period there were no adverse events that lead to drug withdrawal. Thereby, Adalimumab treatment is pathogenetically justified, effective and safe for patients with JIA and uveitis.https://vsp.spr-journal.ru/jour/article/view/519childrentreatmentadalimumabtnf αuveitisjuvenile idiopathic arthritis |
| spellingShingle | E. I. Alexeeva E. V. Mitenko S. I. Valieva T. M. Bzarova R. V. Denisova K. B. Isaeva T. V. Sleptsova A. M. Tchomakhidze EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB Вопросы современной педиатрии children treatment adalimumab tnf α uveitis juvenile idiopathic arthritis |
| title | EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB |
| title_full | EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB |
| title_fullStr | EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB |
| title_full_unstemmed | EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB |
| title_short | EFFICACY AND SAFETY OF PEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS TREATMENT WITH ADALIMUMAB |
| title_sort | efficacy and safety of pediatric juvenile idiopathic arthritis and uveitis treatment with adalimumab |
| topic | children treatment adalimumab tnf α uveitis juvenile idiopathic arthritis |
| url | https://vsp.spr-journal.ru/jour/article/view/519 |
| work_keys_str_mv | AT eialexeeva efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT evmitenko efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT sivalieva efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT tmbzarova efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT rvdenisova efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT kbisaeva efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT tvsleptsova efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab AT amtchomakhidze efficacyandsafetyofpediatricjuvenileidiopathicarthritisanduveitistreatmentwithadalimumab |